Trulieve Cannabis Corp. (CSE:TRUL) shares have continued their recent momentum with a 26% gain in the last month alone. The last month tops off a massive increase of 124% in the last year.
Following the firm bounce in price, given close to half the companies operating in Canada’s Pharmaceuticals industry have price-to-sales ratios (or “P/S”) below 1.3x, you may consider Trulieve Cannabis as a stock to potentially avoid with its 2.1x P/S ratio. Nonetheless, we’d need to dig a little deeper to determine if there is a rational basis for the elevated P/S.
View our latest analysis for Trulieve Cannabis
What Does Trulieve Cannabis’ Recent Performance Look Like?
Trulieve Cannabis hasn’t been tracking well recently as its declining revenue compares poorly to other companies, which have seen some growth in their revenues on average. It might be that many expect the…
